Hologic, Inc. v. Minerva Surgical, Inc.
325 F. Supp. 3d 507
D. Del.2018Background
- Hologic (owner of NovaSure patents) sued Minerva alleging infringement of U.S. Pat. Nos. 6,872,183 (method for detecting uterine perforations) and 9,095,348 (apparatus with applicator head, electrodes, indicator, handle/flexure mechanism). Remaining asserted claims: '183 claims 7, 9, 11, 13, 14 and '348 claim 1.
- Technology: endometrial ablation systems that insufflate the uterus, detect perforations via pressure sensing, deploy an applicator head with electrodes, and remove moisture. Minerva's accused product (Minerva EAS) uses a flow meter/Uterine Integrity Test (UIT), a Plasma Formation Array, and a PFA Width Indicator.
- Procedural posture: Minerva moved to dismiss the '183 claim as moot based on a PTAB final written decision in IPR; Hologic appealed the PTAB decision to the Federal Circuit. Multiple summary judgment and Daubert motions were filed by both sides.
- Key factual nexus: Csaba Truckai (inventor on the patents) founded Minerva after assigning rights to NovaCept (later sold to Hologic); Hologic asserts assignor estoppel/privity to bar Minerva’s invalidity defenses.
- Court construed core claim terms (e.g., “pressure sensor” = device whose input detects, directly or indirectly, a force per unit area and outputs a corresponding electrical signal) and concluded that, applying those constructions, (1) Minerva’s non-infringement and §112 invalidity defenses fail and (2) Hologic has shown infringement on the asserted claims as a matter of law on summary judgment.
Issues
| Issue | Plaintiff's Argument (Hologic) | Defendant's Argument (Minerva) | Held |
|---|---|---|---|
| Mootness of '183 patent suit after PTAB IPR | PTAB decision is subject to appeal; case is not moot | PTAB final written decision extinguishes causes of action and requires dismissal | Denied: appeal pending; patent not canceled and PTAB decision lacks preclusive effect until appeal resolved |
| Assignor estoppel/privity | Truckai assigned patents, founded Minerva, led development and commercialization; equities favor estoppel/privity | Minerva disputes applicability to §112 and argues equities favor competition | Granted: privity found; assignor estoppel bars Minerva’s invalidity defenses |
| §112 written description/enablement (validity) | Specification (with claims) adequately describes/enables claimed elements; no undue experimentation | Specification insufficient for claimed elements; accused device features (plasma formation) not disclosed; undue experimentation | Hologic: Granted summary judgment of no invalidity; Minerva estopped and, alternatively, failed to prove invalidity by clear and convincing evidence |
| Infringement (literal and indirect) | Minerva EAS practices method and apparatus claims; UIT flow meter indirectly detects pressure (Bernoulli), PFA Width Indicator meets "indicator mechanism"; induces customer use | Flow sensor measures flow, not pressure; output not corresponding electrical pressure signal; redesigns/other features avoid infringement | Granted for Hologic: Court found no genuine dispute of material fact and entered summary judgment of infringement (direct, induced, contributory) |
| Doctrine of equivalents / prosecution history estoppel (PHE) | DOE may apply; narrowing amendment not a clear surrender of all equivalents | PTO prosecution added pivot-point limitation to secure patent; PHE forecloses DOE for that element | Denied: Court found no clear and unmistakable surrender; handling redesign not before court and ruling would be advisory |
| Willful infringement / enhanced damages | Hologic points to pre-issuance conduct, copying allegations, and Truckai’s role to support willfulness | Minerva argues patents issued after product development and no deliberate copying | Denied (Minerva’s SJ): Genuine issues of fact on intent and knowledge; willfulness left for jury |
| Unfair competition / Lanham Act and Delaware claims | Hologic alleges deceptive trade practices, disparagement, misrepresentation (e.g., "NovaSure 2.0"), misuse of confidential info, and hiring former sales reps | Minerva contends statements were puffery and Hologic lacks causation/harm evidence | Denied (Minerva’s SJ): Court found genuine issues of material fact on misrepresentations, confusion, disparagement and causation; for jury resolution |
Key Cases Cited
- Kokkonen v. Guardian Life Ins. Co. of Am., 511 U.S. 375 (federal courts have limited jurisdiction; mootness principles)
- Fresenius USA, Inc. v. Baxter Int'l, Inc., 721 F.3d 1330 (Fed. Cir.) (cancellation of claims in USPTO IPR renders related litigation moot only after appeals/ certificate)
- Bettcher Indus., Inc. v. Bunzl USA, Inc., 661 F.3d 629 (Fed. Cir.) (finality of patentability determination after appeals)
- Diamond Sci. Co. v. Ambico, Inc., 848 F.2d 1220 (Fed. Cir.) (assignor estoppel prevents assignor from later asserting invalidity)
- Mentor Graphics Corp. v. EVE-USA, Inc., 851 F.3d 1275 (Fed. Cir.) (doctrine of assignor estoppel remains viable)
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (prosecution history estoppel limits doctrine of equivalents when claim narrowed to obtain patent)
- Halo Elecs., Inc. v. Pulse Elecs., Inc., 136 S. Ct. 1923 (enhanced damages for egregious, willful infringement; discretionary, fact-intensive)
- Daubert v. Merrell Dow Pharm., Inc., 509 U.S. 579 (standards for admissibility of expert testimony)
- Ariad Pharm., Inc. v. Eli Lilly & Co., 598 F.3d 1336 (Fed. Cir.) (written-description requirement analysis)
- i4i Ltd. P'ship v. Microsoft Corp., 564 U.S. 91 (clear-and-convincing evidence standard for invalidity and role of expert methodology)
- Centricut, LLC v. Esab Group, Inc., 390 F.3d 1361 (Fed. Cir.) (expert testimony often required in complex technology infringement disputes)